ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Hot Growth Stocks to Invest in Now. On October 13, Etzer Darout from Barclays initiated ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a $142 price target.
Analysts noted that they initiated coverage on eight companies in the inflammation, immunology, oncology, and rare disease sectors. He elaborated that while investment in small and mid-cap biotechnology stocks has binary risks. However, investments based on the prior clinical data and other de-risked mechanisms present a favorable risk/reward situation that presents significant upside.
Moreover, the firm also believes that the market is currently rewarding new mechanisms and treatments that have the potential to improve dosing and compliance.
In addition to Barclays, earlier on October 10, Yatin Suneja from Guggenheim reiterated a Buy rating on ABIVAX Société Anonyme (NASDAQ:ABVX) with a price target of $150.
ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops antiviral compounds and therapeutic vaccines for severe infectious diseases.
While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
